Sign up to access all valuation multiples
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
1996
3.1K+
Last FY Revenue $175M
Last FY EBITDA $20.1M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, GuangYuYuan Chinese reported revenue of $175M and EBITDA of $20.1M.
GuangYuYuan Chinese expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GuangYuYuan Chinese valuation multiples based on analyst estimates| NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|
| Revenue | XXX | $175M | XXX | XXX | XXX |
| Gross Profit | XXX | $128M | XXX | XXX | XXX |
| Gross Margin | XXX | 74% | XXX | XXX | XXX |
| EBITDA | XXX | $20.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $26.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | 15% | XXX | XXX | XXX |
| Net Profit | XXX | $10.6M | XXX | XXX | XXX |
| Net Margin | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GuangYuYuan Chinese has current market cap of CNY 8.8B (or $1.3B), and EV of CNY 8.6B (or $1.2B).
As of January 16, 2026, GuangYuYuan Chinese's stock price is CNY 18 (or $3).
See GuangYuYuan Chinese trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialGuangYuYuan Chinese's trades at 7.0x EV/Revenue multiple, and 61.1x EV/EBITDA.
See valuation multiples for GuangYuYuan Chinese and 15K+ public compsAs of January 16, 2026, GuangYuYuan Chinese has market cap of $1.3B and EV of $1.2B.
Equity research analysts estimate GuangYuYuan Chinese's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GuangYuYuan Chinese's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 61.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 46.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 118.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 83.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuangYuYuan Chinese's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
GuangYuYuan Chinese's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GuangYuYuan Chinese's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GuangYuYuan Chinese and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GuangYuYuan Chinese acquired XXX companies to date.
Last acquisition by GuangYuYuan Chinese was XXXXXXXX, XXXXX XXXXX XXXXXX . GuangYuYuan Chinese acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was GuangYuYuan Chinese founded? | GuangYuYuan Chinese was founded in 1996. |
| Where is GuangYuYuan Chinese headquartered? | GuangYuYuan Chinese is headquartered in China. |
| How many employees does GuangYuYuan Chinese have? | As of today, GuangYuYuan Chinese has 3.1K+ employees. |
| Is GuangYuYuan Chinese publicy listed? | Yes, GuangYuYuan Chinese is a public company listed on SHG. |
| What is the stock symbol of GuangYuYuan Chinese? | GuangYuYuan Chinese trades under 600771 ticker. |
| When did GuangYuYuan Chinese go public? | GuangYuYuan Chinese went public in 1996. |
| Who are competitors of GuangYuYuan Chinese? | Similar companies to GuangYuYuan Chinese include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GuangYuYuan Chinese? | GuangYuYuan Chinese's current market cap is $1.3B |
| Is GuangYuYuan Chinese profitable? | Yes, GuangYuYuan Chinese is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
